Abstract 706P
Background
NSGCTs with BMs are deemed poor-risk by definition. The data on the use and clinical outcomes of SRS in this cohort of patients (pts) is limited.
Methods
This retrospective audit included all pts with BM from metastatic NSGCT treated with SRS at the Royal Marsden Hospital between 2016 and 2024. Pts were required to meet the commissioning criteria for SRS (controllable/absent extracranial disease, expected prognosis ≥6 months, Karnofsy Performance Status, KPS >70). All pts were discussed in specialist germ cell and SRS MDMs. All were treated using a CyberKnife system.
Results
Ten pts were treated. One received 2 and another 3 courses of SRS; total no. of treatments delivered was 13. Median (IQR) age at diagnosis: 31.5 (22-46) yrs. Median (range) time to SRS from diagnosis: 8 (4-205) mts. 2/10 had mediastinal GCT, 8/10 had testicular GCT. 4/10 had BMs on diagnosis. Median (range) KPS: 90 (70-100). Most common chemotherapy regimens: high-dose stem cell rescue (6/10), TIP (5/10), IPE (4/10), CBOP-BEP (4/10). SRS treatments were: alone (9/13), boost post whole brain radiotherapy, WBRT (2/13), to tumour bed alone post-surgery (2/13). 4/10 pts had WBRT: 3/4 prior to SRS of whom 2/3 received SRS boost, 1/3 received SRS on progression; 1/4 had WBRT after debulking surgery on progression after SRS. Most had 1 BM on planning MRI (6/13). Mean (range) GTV/CTV volume: 4.24 (0.07-15.42) cc. SRS doses: 24Gy/3# (4/13), 24Gy/1# (3/13), 21Gy/1# (3/13), 20Gy/1# (1/13), 18Gy/3# (1/13), 18Gy/1# (1/13). Survival was analysed from date of SRS. Median (range) follow-up: 17 (1-80) mts. There were six instances of intracranial progression in 4/10 pts, all failed extracranially. 7/10 pts progressed extracranially: 1/7 salvaged, 3/7 died, 3/7 are on chemotherapy. Intracranial control: 6/10 pts. Both intracranial and extracranial control: 3/10 pts. Median (95% CI) progression-free survival (PFS): 4 (3-5) months. Mean (95% CI) overall survival (OS): 56 (34-78) mts. Two-year OS and PFS were 67% and 23%. The presence of a mediastinal primary adversely impacted OS (Mantel-Cox P=0.005). Younger age (<40 yrs) or BM at diagnosis did not affect OS or PFS.
Conclusions
The use of SRS achieved durable intracranial control in BM in mNSGCT and is appropriate in carefully selected patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
826P - Efficacy of non-doxorubicin based regimens in severely G6PD deficient patients with DLBCL
Presenter: Shruti Prem Sudha
Session: Poster session 09
827P - Comparison of efficacy and safety between glofitamab and real-world regimens among Chinese patients with 3L+ relapsed/refractory diffuse large B-cell lymphoma: An external control study
Presenter: Keshu Zhou
Session: Poster session 09
828P - Translocation 11;14 is not associated with adverse prognosis in the era of novel anti-myeloma therapeutics
Presenter: Ioannis Ntanasis-Stathopoulos
Session: Poster session 09
829P - Flumatinib combined with chemotherapy for newly diagnosed adult with Ph-positive acute lymphoblastic leukemia: A single-center, retrospective observational study
Presenter: HAN SHUYU
Session: Poster session 09
830P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Poster session 09
Resources:
Abstract
831P - Impact of chronic kidney disease on disease outcomes in hospitalized multiple myeloma patients: A National inpatient sample study from 2016 to 2020
Presenter: Marco Bermudez
Session: Poster session 09
Resources:
Abstract
832P - CLOMB: A validated scoring model to predict the relapse in the central nervous system of pediatric acute B-cell lymphoblastic leukemia
Presenter: Jiacheng Li
Session: Poster session 09
Resources:
Abstract
833P - Latest results of GVM±R regimen for the salvage therapy of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Presenter: Wei Liu
Session: Poster session 09
834P - Treatment of DLBCL in HIV patient: Still a dilemma
Presenter: Devashish Desai
Session: Poster session 09
835P - Genetic, epigenetic, and clinical significance of Wilms’ tumor 1 (WT1) gene in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract